Neoadjuvant chemotherapy for locally advanced breast cancer: A review of the literature and future directions

European Journal of Surgical Oncology

Volumn 35, Issue 2, 2009, Pages 113-122

  Mathew, J ^a   Asgeirsson, K S ^a   Cheung, K L ^a   Chan, S ^a   Dahda, A ^a   Robertson, J F R ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Clinical response; Locally advanced primary breast cancer; Neoadjuvant chemotherapy; Oncoplastic conservation surgery; Pathological response

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EXEMESTANE; FLUOROURACIL; METHOTREXATE; MITOMYCIN; MITOXANTRONE; NAVELBINE; PACLITAXEL; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAXANE DERIVATIVE; TRASTUZUMAB; VINCRISTINE;

ADVANCED CANCER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER LOCALIZATION; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DISEASE FREE SURVIVAL; DRUG RESPONSE; DRUG SAFETY; HUMAN; LYMPH NODE METASTASIS; MASTECTOMY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MASTECTOMY; NEOADJUVANT THERAPY; SURVIVAL RATE; TREATMENT OUTCOME; WORLD HEALTH;

EID: 58149481913     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2008.03.015     Document Type: Review

References (75)

1. Wolff A.C., and Davidson N.E. Preoperative therapy in breast cancer: Lessons from the treatment of locally advanced disease. Oncologist 7 (2002) 239-245
2. Singletary S.E., Allred C., Ashley P., et al. Revision of the American Joint Committee on cancer staging system for breast cancer. J Clin Oncol 20 (2002) 3628-3636
3. West Midlands Cancer Intelligence Unit. 0-10 year relative survival for cases of breast cancer by stage diagnosed in the West Midlands 1985-1989 followed up to the end of 1999, as at January 2002.
4. National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch. SEER Program public use data tapes 1973-1998, November 2000 Submission. Issued: April 2001.
5. Haagensen C.D., and Stout A.P. Carcinoma of breast. II. Criteria of operability. Ann Surg 118 (1943) 859-868
6. Williams M.R., Gilson D., Marsh L., et al. The early results from a randomised study of radiotherapy versus Nolvadex (tamoxifen) as initial treatment for stage III breast cancer. Eur J Surg Oncol 14 (1988) 235-240
7. Rubens R.D., Bartelink H., Engelsman E., et al. Locally advanced breast cancer: the contribution of cytotoxic and endocrine treatment to radiotherapy. An EORTC breast cancer co-operative group trial (10792). Eur J Cancer Clin Oncol 25 (1989) 667-678
8. Tan S.M., Cheung K.L., Willsher P.C., Blamey R.W., Chan S.Y., and Robertson J.F.R. Locally advanced primary breast tumour: medium-term results of a randomised controlled trial of multimodal therapy versus initial hormone therapy. Eur J Cancer 37 (2001) 2331-2338
9. Willsher P.C., Robertson J.F.R., Chan S.Y., Jackson L., and Blamey R.W. Locally advanced breast cancer: Early results of a randomised trial of multimodal therapy versus initial hormone therapy. Eur J Cancer 33 (1997) 45-49
10. De Lena M., Zucali R., Viganotti G., et al. Combined chemotherapy- radiotherapy approach in locally advanced (T3b-T4) breast cancer. Cancer Chemotherapy Pharmacol 1 (1978) 53-59
11. Wolmark N., Wang J., Mamounas E., et al. Preoperative chemotherapy in patients with operable breast cancer: nine year results from National Surgical Adjuvant Breast and Bowel project B-18. J Natl Cancer Inst Monogr 30 (2001) 96-102
12. Heys S.D., Hutcheon A.W., Sarkar T.K., et al. on behalf of the Aberdeen breast group. Neoadjuvant Docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer Suppl 3 suppl (2002) 69-74
13. Thomas E., Homes F.A., Smith T.L., et al. The use of alternative, non-cross resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: Long-term results from a prospective randomised trial. J Clin Oncol 22 (2004) 2294-2302
14. Therasse P., Mauriac L., Welnicka-Jaskiewicz M., et al. Final results of a randomized Phase III trial comparing cyclophosphamide, Epirubicin, and Flurouracil with a dose intensified epirubicin and cyclophosphamide+Filgrastim as neoadjuvant treatment in locally advanced breast cancer: An EORTC-NCIC-SAKK multicenter study. J Clin Oncol 21 (2003) 843-850
15. Semiglazov V.F., Semigloazov V.V., Dashyan G.A., et al. Phase 2 randomised trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer 110 (2007) 244-254
16. Ezzat A.A., Ibrahim E.M., Ajarim D.S., et al. Phase II study of neoadjuvant paclitaxel and cisplatin for operable and locally advanced breast cancer: analysis of 126 patients. Br J Cancer 90 (2004) 968-974
17. Matteis A.D., Nuzzo F., D'Aiuto G., et al. Docetaxel plus epidoxorubicin as neoadjuvant treatment inpatients with large operable or locally advanced carcinoma of the breast. Cancer 94 (2002) 895-901
18. Lebowitz P.F., Eng-Wong J., Swain S.M., et al. A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer. Clin Cancer Res 10 (2004) 6764-6769
19. Espinosa E., Morales S., Borrega P., et al. Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer. Cancer Chemother Pharmacol 54 (2004) 546-552
20. Kao J., Conzen S., Jaskowiak N., Song D., et al. Concomitant radiation therapy and pacitaxel for unresectable locally advanced breast cancer: results from two consecutive phase I/II trials. Int J Radiat Oncol Biol Phys 61 (2005) 1045-1053
21. Tham Y., Gomez L.F., Mohsin S., et al. Clinical response to neoadjuvant docetaxel predics improved outcome in patients with large locally advanced breast cancers. Breast Cancer Res Treat 94 (2005) 279-284
22. Gradishhar W., Wedam B., Jahanzeb M., et al. Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer. Ann Oncol 16 (2005) 1297-1304
23. Kuerer H., Newman L., Smith T., et al. Clinical course of breast cancer patients with complete pathologic primary tumour and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17 (1999) 460-469
24. Clark J., Roseman J., Cance W., Halle J., and Graham M. Extending the indications for breast-conserving treatment to patients with locally advanced breast cancer. Int J Radiat Oncol Biol Phys 42 (1998) 345-350
25. Shen J., Valero V., Buchholz T.A., et al. Effective local control and long-term survival in patients with T4 locally advanced breast cancer treated with breast conservation therapy. Ann Surg Oncol 11 (2004) 854-860
26. Huang E., Tucker S., Strom E., et al. Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys 62 (2005) 351-357
27. Baldini E., Gardin G., Evangelista G., Prochio T., Collecchi P., and Lionetto R. Long term results of combined-modality therapy for inflammatory breast carcinoma. Clin Breast Cancer 5 (2004) 358-363
28. Erol K., Baltali E., Altundag K., et al. Neoadjuvant chemotherapy with cyclophosphamide, methotrexate and 5-flurouracil in locally advanced breast cancer. Onkologie 28 (2005) 81-85
29. Kim R., Osaki A., Tanabe K., and Toge T. Neoadjuvant chemotherapy for local advanced breast cancer with stage III B. Oncology Rep 11 (2004) 1265-1272
30. McIntosh S., Ogston K., Payne S., et al. Local recurrence in patients with large and locally advanced breast cancer treated with primary chemotherapy. Am J Surg 185 (2003) 525-531
31. Favret A., Carlson R., Goffinet D., Jeffrey S., Dirbas F., and Stockdale F. Locally advanced breast cancer: Is surgery necessary?. Breast J 7 (2001) 131-137
32. Asoglu O., Muslumanoglu M., Igci A., et al. Breast conservation surgery after primary chemotherapy in locally advanced breast cancer. Acta Chir Belg 105 (2005) 62-68
33. Colozza M., Gori S., Mosconi A.M., et al. Induction chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (CAP) in a combined modality approach for locally advanced and inflammatory breast cancer. Long term results. Am J Clin Oncol 19 (1996) 10-17
34. Gajdos C., Tartter P., Estabrook A., et al. Relationship of clinical and pathological response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer. J Surg Oncol 80 (2002) 4-11
35. Bear D.B., Anderson S., Brown A., et al. The effect on tumour response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide; Preliminary results from national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol 21 (2003) 4165-4174
36. Bear D.B., Anderson S., Smith R.E., et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National surgical adjuvant breast and bowel project B-27. J Clin Oncol 24 (2006) 2019-2027
37. von Minckwitz G., Raab G., Caputo A., et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: The GEPARDUO study of the German Breast Group. J Clin Oncol 23 (2005) 2676-2685
38. von Minckwitz G., Blohmer J.-U., Raab G., et al. In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol 16 1 (2005) 56-63
39. Gianni L., Semiglazov V., Manikhas G.M., et al. Neoadjuvant trastuzumab in locally advanced breast cancer (NOAH): Antitumour and safety analysis. 2007 ASCO Annual Meeting Proceedings. J Clin Oncol 25 18 suppl (2007) 532
40. Buzdar A., Valero V., Ibrahim N., et al. Neoadjuvant therapy with paclitaxel followed by 5-flurouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent tratuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomised study population and data of additional patients treated with the same regimen. Clin Cancer Res 13 (2007) 228-233
41. Rugo H.S. Bevacizumab in the treatment of breast cancer: rationale and current data. Oncologist 9 (2004) 43-49
42. Lyons J.A., Silverman P., Remick S., et al. Toxicity results and early outcome data on a randomised phase II study of docetaxel + or - bevacizumab for locally advanced, unrespectable breast cancer. J Clin Oncol 24 (2006) 3049 (Abstract)
43. Kaufmann M., von Minckwitz G., Bear H.D., et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 18 (2006) 1927-1934
44. Sorlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98 (2001) 10869-10874
45. Early Breast Cancer Trialists collaborative group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of randomised trials. Lancet 365 (2005) 1687-1717
46. Rouzier R., Pusztai L., Delaloge S., et al. Nomograms to predict pathologic complete response and metastasis free survival after preoperative chemotherapy for breast cancer. J Clin Oncol 23 (2005) 8331-8339
47. Mathieu M.-C., Rouzier R., Llombart-Cussac A., et al. The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. Eur J Cancer 40 (2004) 342-351
48. Cristofanilli M., Gonzalez-Angulo A., and Sneige N. Invasive lobular carcinoma classic type: Response to primary chemotherapy and survival outcomes. J Clin Oncol 23 (2005) 41-48
49. Hutcheon A.W., Heys S.D., Sarkar T.K., et al. Docetaxel primary chemotherapy in breast cancer: a five year update of the Aberdeen trial. Breast Cancer Res Treat 82 Suppl 1 (2003) S9 (Abstract 11)
50. Recht A., and Houlihan M.J. Axillary lymph nodes and breast cancer. Cancer 76 (1995) 1491-1512
51. Pierga J.Y., Mouret E., Dieras V., et al. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer. Br J Cancer 83 (2000) 1480-1487
52. Veronesi U., Bonadonna G., Zurrida S., et al. Conservation surgery after primary chemotherapy in large carcinomas of the breast. Ann Surg 222 (1995) 612-618
53. Rouzier R., Extra J., Klijanienko J., et al. Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumours and cytologically proven axillary metastatic lymph nodes. J Clin Oncol 20 (2002) 1304-1310
54. Kuerer H., Newman L., Buzdar M.D., et al. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg 176 (1998) 502-509
55. Van der Hage J.A., Van der Hage C.J.H., Julian J., et al. Preoperative chemotherapy in primary operable breast cancer: results from the European organization for research and treatment of cancer trial 10902. J Clin Oncol 19 (2001) 4224-4237
56. Mieog J.S.D., and van der Hage J.A. van de Velde CJH. Neoadjuvant chemotherapy for operable breast cancer. Br J Surg 94 (2007) 1189-1200
57. Clouth B., Chandrasekharan S., Inwang R., Smith S., Davidson N., and Sauven P. The surgical management of patients who achieve a complete pathological response after primary chemotherapy for locally advanced breast cancer. Eur J Surg Oncol 33 (2007) 961-966
58. Mueiac L., MacGorgan G., Avril A., et al. Neoadjuvant chemotherapy for operable breast cancer larger than 3 cm: A unicentre randomized trial with a 124-month median follow up. Ann Oncol 10 (1999) 47-52
59. Scholl S.M., Pierga J.Y., Asselain B., et al. Breast cancer response to primary chemotherapy predicts local and distant control as well as survival. Eur J Cancer 31A (1995) 1969-1975
60. Broet P., Scholl S.M., De La Rochefordiere A., et al. Short and long term effects on survival in breast cancer patients treated by primary chemotherapy: an updated analysis of a randomised trial. Breast Cancer Res Treat 58 (1999) 151-156
61. Fisher B., Bryant J., Wolmark N., et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16 (1998) 2672-2685
62. Semiglazlov V.F., Topuzov E.E., Bavli J.L., et al. Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer. Ann Oncol 9 (1998) 1179-1184
63. Powles T.J., Hickish T.F., and Markis A. Randomised trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 13 (1995) 547-552
64. Makris A., Powles T.J., Ashley S.E., et al. A reduction in requirements for mastectomy in a randomised trial of neoadjuvant chemoendocrine therapy in breast cancer. Ann Oncol 9 (1998) 1179-1184
65. Gardin G., Rosso R., Campora E., et al. Locally advanced non-metastatic breast cancer: Analysis of prognostic factors in 125 patients homogeneously treated with a combined modality approach. Eur J Cancer 31A (1995) 1428-1433
66. Von Minckwitz G., Costa S.D., Eiermann W., et al. Maximized reduction of primary breast tumour size using pre-operative chemotherapy with doxorubicin and docetaxel. J Clin Oncol 17 (1999) 1999-2005
67. Banadonna G., Valagussa P., Brambilla C., et al. Primary chemotherapy in operable breast cancer: Eight year experience at Milan cancer institute. J Clin Oncol 16 (1998) 93-100
68. Khanna M., Mark R., Silverstein M., et al. Breast conservation management of breast tumours 4 cm or larger. Arch Surg 127 (1992) 1038-1043
69. Asgeirsson K.S., McCulley S.J., Pinder S.E., and Macmillan R.D. Size of invasive breast cancer and risk of local recurrence after breast conservation therapy. Eur J Cancer 39 17 (2003) 2462-2469
70. Edeiken B.S., Fornage B.D., Bedi D.G., et al. US-guided implantation of metallic markers for permanent localization of the tumour bed in patients with breast cancer who undergo preoperative chemotherapy. Radiology 213 (1999) 895-900
71. Mumtaz H., Hall-Craggs M.A., Davidson T., et al. Staging of symptomatic primary breast cancer with MR imaging. AJR Am J Roentgenol 169 (1997) 417-424
72. Fischer U., Kopka L., and Grabbe E. Breast carcinoma: effect of preoperative contrast-enhancement MR imaging on the therapeutic approach. Radiology 213 (1992) 881-888
73. Partridge S.C., Gibbs J.E., Lu Y., et al. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. AJR Am J Roentgenol 179 (2002) 1193-1199
74. Garimella V., Qutob O., Fox J.N., et al. Recurrences rates after DCE-MRI image guided planning for breast-conserving surgery following neoadjuvant chemotherapy for locally advanced breast cancer patients. Eur J Surg Oncol 33 (2007) 157-161
75. 18F) FDG PRT for pathological response of breast cancer to neo-adjuvant chemotherapy. Ann Oncol 15 (2004) 1352-1357